- Home
- NEO vs SABR Comparison
NEO vs SABR Comparison
Compare NEO & SABR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEO
- SABR
- Stock Information
- Founded
- NEO 2001
- SABR 2006
- Country
- NEO United States
- SABR United States
- Employees
- NEO N/A
- SABR N/A
- Industry
- NEO Precision Instruments
- SABR Computer Software: Programming Data Processing
- Sector
- NEO Health Care
- SABR Technology
- Exchange
- NEO Nasdaq
- SABR Nasdaq
- Market Cap
- NEO 965.2M
- SABR 981.2M
- IPO Year
- NEO 1999
- SABR 2014
- Fundamental
- Price
- NEO $7.00
- SABR $2.63
- Analyst Decision
- NEO Buy
- SABR Hold
- Analyst Count
- NEO 9
- SABR 5
- Target Price
- NEO $13.31
- SABR $4.12
- AVG Volume (30 Days)
- NEO 2.0M
- SABR 5.6M
- Earning Date
- NEO 07-28-2025
- SABR 07-31-2025
- Dividend Yield
- NEO N/A
- SABR N/A
- EPS Growth
- NEO N/A
- SABR N/A
- EPS
- NEO N/A
- SABR N/A
- Revenue
- NEO $672,361,000.00
- SABR $3,023,296,000.00
- Revenue This Year
- NEO $13.97
- SABR $2.85
- Revenue Next Year
- NEO $11.36
- SABR $3.47
- P/E Ratio
- NEO N/A
- SABR N/A
- Revenue Growth
- NEO 10.10
- SABR 2.56
- 52 Week Low
- NEO $6.08
- SABR $1.93
- 52 Week High
- NEO $19.12
- SABR $4.63
- Technical
- Relative Strength Index (RSI)
- NEO 40.74
- SABR 46.92
- Support Level
- NEO $6.90
- SABR $2.57
- Resistance Level
- NEO $7.42
- SABR $3.03
- Average True Range (ATR)
- NEO 0.39
- SABR 0.14
- MACD
- NEO -0.00
- SABR -0.02
- Stochastic Oscillator
- NEO 13.01
- SABR 29.20
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
About SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The travel solutions segment represented 91% of total 2024 revenue, split between distribution (79% of segment sales) and airline IT solutions (21%) revenue. The company also has a growing hotel IT solutions division (9% of revenue). Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.